Drug Profile
Research programme: TNF-alpha inhibitors - Biota Holdings
Latest Information Update: 29 May 2007
Price :
$50
*
At a glance
- Originator Biota Holdings
- Class Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 24 Nov 2003 Preclinical trials in Rheumatoid arthritis in Australia (unspecified route)